Orchid Pharma Releases FY25-26 BRSR Highlighting Operational and Sustainability Metrics
Orchid Pharma Ltd · Others (Uncategorized) · 08 Sept 2026, 9:32 pm
Orchid Pharma Releases FY25-26 BRSR Highlighting Operational and Sustainability Metrics Orchid Pharma reported FY25-26 standalone turnover of ₹1,23,277.84 lakh and net worth of ₹1,64,667.59 lakh, with Active Pharmaceutical Ingredients (APIs), primarily Cephalosporin, generating 97% of total revenue. Exports contributed 64.55% across 52 countries. Total energy consumption stood at 1,498.12 Joules, with renewable sources comprising 68% of electricity and wind/solar usage. Total Scope 1 and Scope 2 GHG emissions declined to 54,412.00 metric tonnes and 12,806.00 metric tonnes of CO2 equivalent, respectively. The company maintains a 100% Zero Liquid Discharge system across its operations.
Original exchange filing (PDF)
More announcements from Orchid Pharma Ltd
- Audio Recording of the Analysts/Investors Earnings Call - Orchid Pharma Limited ('the Company') · 18 Nov 2026
- Board Comments on fine levied by Stock Exchanges · 17 Nov 2026
- Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026 · 17 Nov 2026
- Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP) · 14 Nov 2026
- Declaration of Financial results for quarter and half year ended on September 30, 2026 · 14 Nov 2026
- Outcome of Board Meeting · 14 Nov 2026
- Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 14 Nov 2026
- Monitoring Agency Report for the Quarter-II ended on September 30, 2026 · 14 Nov 2026
